Drug-induced oral lichenoid reaction during nivolumab therapy

International Journal of Oral and Maxillofacial Surgery
Y EnomotoY Tsuchiya

Abstract

Oral lichenoid reaction, an immune-related adverse event of immunotherapy, has been reported in very few patients receiving anti-programmed cell death receptor-1 (anti-PD-1) therapy. Here, we describe a case of severe stomatitis (grade ≥3 by the Common Terminology Criteria for Adverse Events, version 4.0) accompanied by pharyngolaryngitis that was observed in a patient receiving nivolumab therapy. The stomatitis was diagnosed as drug-induced lichenoid reaction. Nivolumab therapy was discontinued, and the patient was administered systemic prednisolone (1mg/kg). Most of the patient's mucosal changes in the oral cavity and pharyngolarynx resolved within approximately 3 weeks after starting the prednisolone. Clinicians should be aware that severe oral lichenoid reactions can occur in patients receiving anti-PD-1 therapy.

Citations

Apr 4, 2021·Journal of Clinical Medicine·Emi DikaSimone Ribero
Oct 31, 2021·Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry·Marcella Ferreira GobbiLuciana Corrêa
Nov 2, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bryan J SchneiderKathryn Bollin
Feb 3, 2022·Cutaneous and Ocular Toxicology·Maitry BhardwajSangeeta Pilkhwal Sah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis